#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Liposarcoma Autoimmune demyelinating disease Myxoid liposarcoma Chronic graft versus host disease in liver Leukocyte adhesion deficiency type I Spina bifida Infertility male Brain abscess Philadelphia positive chronic myeloid leukaemia Juvenile chronic myelomonocytic leukaemia Ichthyosis Nodal marginal zone B-cell lymphoma Cystic fibrosis respiratory infection suppression Fabry's disease Anaplastic large cell lymphoma T- and null-cell types More trials…

    Learn about Rare Diseases

    Haemophilia Primary hyperoxaluria Hereditary ataxia Angiosarcoma – Basic Information Synovial sarcoma recurrent – Life with Disease Skin angiosarcoma – Diagnostics Wiskott-Aldrich syndrome – Life with Disease Optic glioma – Basic Information Chondrosarcoma Mucopolysaccharidosis – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Pyridoxine Hydrochloride Betaine Citrate Triglycerides, Medium Chain Doravirine Doxycycline Hyclate Mercaptopurine LUNRESERTIB Pf-06835375 Acetazolamide Sodium Vonafexor Crisantaspase Fluticasone Zalunfiban PEGZILARGINASE Spesolimab Latozinemab Carbasalate Calcium Felzartamab Hypothalamic Phospholipids Mexiletine Hydrochloride More therapies…

    Learn about Your Condition

    Adenomatous polyposis coli Critical illness Alagille syndrome Carpal tunnel syndrome Chronic fatigue syndrome Cutaneous sarcoidosis Follicular lymphoma stage II Hypocalcaemia Diabetic autonomic neuropathy Connective tissue disorder Pneumococcal infection Cardiac failure chronic Infectious pleural effusion KBG syndrome Osteoporosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Oscar Lambret

Centre Oscar Lambret

3 Rue Frederic Combemale, Lille, 59000, France

Want to learn more about this study or check if you can participate? Contact us.

  • Evaluation of COM701 as Maintenance Therapy for Patients with Relapsed Platinum-Sensitive Ovarian Cancer

    Recruiting

    1 1 1
    Investigated Drugs:
    • HUMANISED IGG4 MONOCLONAL ANTIBODY AGAINST PVRIG
    • Saline
    France

  • Study of Temozolomide, Topotecan, Bevacizumab, Irinotecan and Dinutuximab Beta in Patients with High-Risk Relapsed Neuroblastoma

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Dinutuximab Beta
    • Temozolomide
    • Bevacizumab
    Austria Belgium Denmark France Germany Italy +4

  • Study of Regorafenib and Maintenance Chemotherapy for Newly Diagnosed Ewing Sarcoma Patients with Metastatic Disease

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ewing’s sarcoma
    Investigated Drugs:
    • Vinorelbine
    • Cyclophosphamide
    Denmark France The Netherlands Norway Spain

  • Study of NBTXR3 and Cetuximab for Elderly Patients with Advanced Head and Neck Cancer Ineligible for Platinum Chemotherapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Head and neck cancer
    Investigated Drugs:
    • HAFNIUM OXIDE
    • Cetuximab
    Austria Belgium Czechia France Germany Greece +4

  • Study on the Safety and Effects of MK-3120 for Patients with Advanced Solid Tumors

    Recruiting

    1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • SKB410
    France The Netherlands Poland Spain

  • Study of Relacorilant, Nab-Paclitaxel, and Bevacizumab for Patients with Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Peritoneal neoplasm
    • Fallopian tube cancer
    • Endometrial cancer
    Investigated Drugs:
    • Relacorilant
    • Bevacizumab
    • Paclitaxel Albumin-Bound
    Belgium France Germany Italy Poland Spain

  • Study of Trastuzumab Deruxtecan and Drug Combination for Patients with Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Capecitabine
    • Cisplatin
    • Fluorouracil
    Austria Belgium Czechia France Germany Italy +6

  • Study of inavolisib, palbociclib and letrozole combination for patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

    Recruiting

    3 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Inavolisib
    • Letrozole
    • Palbociclib
    France Germany Italy Poland Spain

  • Study on the Effects of Darolutamide and Drug Combination for Patients with Metastatic Hormone-Naïve Prostate Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Degarelix
    • Leuprorelin Acetate
    • Relugolix
    Belgium Croatia Czechia Denmark France Ireland +4

  • Study of Sacituzumab Tirumotecan and Bevacizumab for Patients with Recurrent Ovarian Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Bevacizumab
    • Buclizine Hydrochloride
    • Codeine Phosphate
    Austria Belgium Czechia Denmark Finland France +8
Previous Page
1 2 3 4 5 6 … 26
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!